At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 34 enrolled
Drug / intervention
tazarotene +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Randomized, Double-Blind, Vehicle-Controlled, Crossover Clinical Trial of Tazarotene 0.1% and Vehicle Cream Each Applied Once-Daily for 12 or 24 Months in Subjects With Basal Cell Nevus Syndrome
In Brief
A Phase 2 clinical trial evaluating tazarotene and placebo for Skin Carcinoma. Completed, enrolled 34 participants across 3 sites.
Detailed Summary
RATIONALE: Drugs used in chemotherapy, such as tazarotene, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This randomized phase II trial is comparing two different schedules of topical tazarotene and topical placebo to see how well they work in treating patients with basal cell skin cancer and basal cell nevus syndrome on the chest.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSkin Carcinoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2004
First PostedNov 2008
Primary CompletionJun 2012
Study CompletionJan 2014
TodayJul 2026
First PostedNov 3, 2008
Enrollment StartJul 1, 2004
Primary CompletionJun 1, 2012
Study CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 7.9 yearsPosted 17.7 years ago
Interventions
tazarotenedrug
Applied to the skin
placeboother
Applied to the skin